Literature DB >> 19945241

Comparison of conventional time-intensity curves vs. maximum intensity over time for post-processing of dynamic contrast-enhanced ultrasound.

Moritz Palmowski1, Wiltrud Lederle, Jessica Gaetjens, Michaela Socher, Peter Hauff, Jessica Bzyl, Wolfhard Semmler, Rolf W Günther, Fabian Kiessling.   

Abstract

Our aim was to prospectively compare two post-processing techniques for dynamic contrast-enhanced ultrasound and to evaluate their impact for monitoring antiangiogenic therapy. Thus, mice with epidermoid carcinoma xenografts were examined during administration of polybutylcyanoacrylate-microbubbles using a small animal ultrasound system (40 MHz). Cine loops were acquired and analyzed using time-intensity (TI) and maximum intensity over time (MIOT) curves. Influences of fast (50 microl/2s) vs. slow (50 microl/10s) injection of microbubbles on both types of curves were investigated. Sensitivities of both methods for assessing effects of antiangiogenic treatment (SU11248) were examined. Correlative histological analysis was performed for vessel-density. Mann-Whitney test was used for statistical analysis. Microbubble injection rates significantly influenced upslope, time-to-peak and peak enhancement of conventional TI curves (p<0.05) but had almost no impact on maximum enhancement of MIOT curves (representing relative blood volume). Additionally, maximum enhancement of MIOT curves captured antiangiogenic therapy effects more reliably and earlier (already after 1 day of therapy; p<0.05) than peak enhancement of TI curves. Immunohistochemistry validated the significantly (p<0.01) lower vessel densities in treated tumors and high correlation (R(2)=0.95) between vessel-density and maximum enhancement of MIOT curves was observed. In conclusion, MIOT is less susceptible to variations of the injection's speed. It enables to assess changes of the relative blood volume earlier and with lower standard deviations than conventional TI curves. It can easily be translated into clinical practice and thus may provide a promising tool for cancer therapy monitoring. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19945241     DOI: 10.1016/j.ejrad.2009.10.030

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  19 in total

1.  Development and validation of an intrinsic landmark-based gating protocol applicable for functional and molecular ultrasound imaging.

Authors:  Christoph Grouls; Max Hatting; Isabelle Tardy; Jessica Bzyl; Georg Mühlenbruch; Florian F Behrendt; Tobias Penzkofer; Christian Trautwein; Christiane Kuhl; Fabian Kiessling; Moritz Palmowski
Journal:  Eur Radiol       Date:  2012-03-30       Impact factor: 5.315

2.  Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials.

Authors:  Edward Leen; Michalakis Averkiou; Marcel Arditi; Peter Burns; Daniela Bokor; Thomas Gauthier; Yuko Kono; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2012-07       Impact factor: 5.315

3.  Quantitative assessment of tumor angiogenesis using real-time motion-compensated contrast-enhanced ultrasound imaging.

Authors:  Marybeth A Pysz; Ismayil Guracar; Kira Foygel; Lu Tian; Jürgen K Willmann
Journal:  Angiogenesis       Date:  2012-04-26       Impact factor: 9.596

4.  A low molecular weight zinc2+-dipicolylamine-based probe detects apoptosis during tumour treatment better than an annexin V-based probe.

Authors:  Karin Palmowski; Anne Rix; Wiltrud Lederle; Florian F Behrendt; Felix M Mottaghy; Brian D Gray; Koon Y Pak; Moritz Palmowski; Fabian Kiessling
Journal:  Eur Radiol       Date:  2014-02       Impact factor: 5.315

5.  Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy.

Authors:  Shashank R Sirsi; Molly L Flexman; Fotois Vlachos; Jianzhong Huang; Sonia L Hernandez; Hyun Keol Kim; Tessa B Johung; Jeffrey W Gander; Ari R Reichstein; Brooke S Lampl; Antai Wang; Andreas H Hielscher; Jessica J Kandel; Darrell J Yamashiro; Mark A Borden
Journal:  Ultrasound Med Biol       Date:  2012-03-16       Impact factor: 2.998

6.  Quantitative contrast-enhanced ultrasound imaging: a review of sources of variability.

Authors:  M-X Tang; H Mulvana; T Gauthier; A K P Lim; D O Cosgrove; R J Eckersley; E Stride
Journal:  Interface Focus       Date:  2011-05-18       Impact factor: 3.906

7.  Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer.

Authors:  Huaijun Wang; Amelie M Lutz; Dimitre Hristov; Lu Tian; Jürgen K Willmann
Journal:  Radiology       Date:  2016-08-04       Impact factor: 11.105

8.  Molecular and functional ultrasound imaging in differently aggressive breast cancer xenografts using two novel ultrasound contrast agents (BR55 and BR38).

Authors:  Jessica Bzyl; Wiltrud Lederle; Anne Rix; Christoph Grouls; Isabelle Tardy; Sibylle Pochon; Monica Siepmann; Tobias Penzkofer; Michel Schneider; Fabian Kiessling; Moritz Palmowski
Journal:  Eur Radiol       Date:  2011-05-12       Impact factor: 5.315

9.  The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55).

Authors:  Jessica Bzyl; Moritz Palmowski; Anne Rix; Susanne Arns; Jean-Marc Hyvelin; Sibylle Pochon; Josef Ehling; Simone Schrading; Fabian Kiessling; Wiltrud Lederle
Journal:  Eur Radiol       Date:  2012-08-10       Impact factor: 5.315

Review 10.  Targeted contrast-enhanced ultrasound: an emerging technology in abdominal and pelvic imaging.

Authors:  Marybeth A Pysz; Jürgen K Willmann
Journal:  Gastroenterology       Date:  2011-01-18       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.